SCYNEXIS INC (SCYX)
US8112922005 - Common Stock
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
SCYX stock results show that SCYNEXIS beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SCYNEXIS (NASDAQ:SCYX) just reported results for the first quarter of 2024.SCYN...
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SCYNEXIS (NASDAQ:SCYX) just reported results for the fourth quarter of 2023.SCY...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study...
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of...
SCYX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
WHY: NEW YORK, NY - (NewMediaWire) - January 8, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the “Class Period”), of the important January 8, 2024 lead plaintiff deadline.
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
/PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against...
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
/PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...
SCYX DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...
SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SCYNEXIS, Inc. ("Scynexis" or the...
Scynexis stock falls as GSK amends deal for Brexafemme
Scynexis (SCYX) stock dropped 9% after its license agreement for antifungal drug Brexafemme was amended by GSK (GSK) due to a recent product recall. Read more here.
SCYX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
/PRNewswire/ -- WHY: New York, N.Y., December 31, 2023. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...
SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SCYNEXIS, Inc. ("Scynexis" or the...
TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31,...
ROSEN, LEADING INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SCYNEXIS, Inc. ("Scynexis" or the...